Posted by aabag on May 22, 2006, at 10:57:12
In reply to Re: EMSAM- is there a new competitor in the works » Last Chance, posted by lymom3 on May 21, 2006, at 21:19:15
I guess its nuts, but when consider the multitude of tests you must go through to ultimately get a drug approved, that costs there too are nuts. In an of itself, each drug, with the efficacy trials, safety trials, animal trials, research staff salaries and materials, carcincinogenicity tests, drug-drug interaction tests, filing costs...its amazing that all but the largest companies can get new products to market.
For example, the concept of GABA-A receptor subtype specific anxiolytics has been around since 1980 or thereabouts, yet we have yet to have a single compound on the market to take advantage of this. Ocinaplon almost made it, but was shut down due to liver issues. I now see other companies cropping up (Neurion) around the same concept, and Dov Pharmaceutical, if it survives the multi-million dollar loss w/ the recent FDA "dis"-approval, will also continue working in this area. If I had the sales leadership, I'm half inclined to get some investors together to work on this area, because non-sedative, non-dependency producing anxiolytics are needed and their would be a massive market for them.
poster:aabag
thread:646057
URL: http://www.dr-bob.org/babble/20060520/msgs/646856.html